| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| October 11th, 2004 | 21 | Yes |
1-(tert-Butyl)-3-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 3.00 | 8.7 | -8.34 | 2 | 5 | 0 | 70 | 281.363 | 2 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| ALOGPS_SOLUBILITY | 9.53e-02 g/l | DrugBank-experimental |
| Target | Src | Selleck Chemicals |
| Indications | Src family tyrosine kinase inhibitor | KeyOrganics Bioactives |
| PUBCHEM_PATENT_ID | WO2000042042A2 | IBM Patent Data |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| CSK-1-E | Tyrosine-protein Kinase CSK (cluster #1 Of 1), Eukaryotic | Eukaryotes | 640 | 0.41 | Binding ≤ 10μM |
| KC1D-1-E | Casein Kinase I Delta (cluster #1 Of 1), Eukaryotic | Eukaryotes | 170 | 0.45 | Binding ≤ 10μM |
| LCK-1-E | Tyrosine-protein Kinase LCK (cluster #1 Of 4), Eukaryotic | Eukaryotes | 40 | 0.49 | Binding ≤ 10μM |
| MK14-1-E | MAP Kinase P38 Alpha (cluster #1 Of 3), Eukaryotic | Eukaryotes | 2800 | 0.37 | Binding ≤ 10μM |
| RIPK2-1-E | Serine/threonine-protein Kinase RIPK2 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 26 | 0.51 | Binding ≤ 10μM |
| SRC-1-E | Tyrosine-protein Kinase SRC (cluster #1 Of 3), Eukaryotic | Eukaryotes | 170 | 0.45 | Binding ≤ 10μM |
| TIE2-1-E | Tyrosine-protein Kinase TIE-2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 7000 | 0.34 | Binding ≤ 10μM |
| VGFR2-1-E | Vascular Endothelial Growth Factor Receptor 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 1600 | 0.39 | Binding ≤ 10μM |
| Z81072-1-O | Jurkat (Acute Leukemic T-cells) (cluster #1 Of 10), Other | Other | 400 | 0.43 | Functional ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| KC1D_HUMAN | P48730 | Casein Kinase I Delta, Human | 170 | 0.45 | Binding ≤ 1μM |
| MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 1000 | 0.40 | Binding ≤ 1μM |
| RIPK2_HUMAN | O43353 | Serine/threonine-protein Kinase RIPK2, Human | 26 | 0.51 | Binding ≤ 1μM |
| CSK_HUMAN | P41240 | Tyrosine-protein Kinase CSK, Human | 640 | 0.41 | Binding ≤ 1μM |
| LCK_HUMAN | P06239 | Tyrosine-protein Kinase LCK, Human | 151 | 0.45 | Binding ≤ 1μM |
| LCK_MOUSE | P06240 | Tyrosine-protein Kinase LCK, Mouse | 40 | 0.49 | Binding ≤ 1μM |
| SRC_CHICK | P00523 | Tyrosine-protein Kinase SRC, Chick | 53 | 0.49 | Binding ≤ 1μM |
| SRC_HUMAN | P12931 | Tyrosine-protein Kinase SRC, Human | 170 | 0.45 | Binding ≤ 1μM |
| KC1D_HUMAN | P48730 | Casein Kinase I Delta, Human | 170 | 0.45 | Binding ≤ 10μM |
| MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 1000 | 0.40 | Binding ≤ 10μM |
| RIPK2_HUMAN | O43353 | Serine/threonine-protein Kinase RIPK2, Human | 26 | 0.51 | Binding ≤ 10μM |
| CSK_HUMAN | P41240 | Tyrosine-protein Kinase CSK, Human | 640 | 0.41 | Binding ≤ 10μM |
| LCK_MOUSE | P06240 | Tyrosine-protein Kinase LCK, Mouse | 40 | 0.49 | Binding ≤ 10μM |
| LCK_HUMAN | P06239 | Tyrosine-protein Kinase LCK, Human | 151 | 0.45 | Binding ≤ 10μM |
| SRC_CHICK | P00523 | Tyrosine-protein Kinase SRC, Chick | 53 | 0.49 | Binding ≤ 10μM |
| SRC_HUMAN | P12931 | Tyrosine-protein Kinase SRC, Human | 170 | 0.45 | Binding ≤ 10μM |
| TIE2_HUMAN | Q02763 | Tyrosine-protein Kinase TIE-2, Human | 7000 | 0.34 | Binding ≤ 10μM |
| VGFR2_HUMAN | P35968 | Vascular Endothelial Growth Factor Receptor 2, Human | 1600 | 0.39 | Binding ≤ 10μM |
| Z81072 | Z81072 | Jurkat (Acute Leukemic T-cells) | 1200 | 0.39 | Functional ≤ 10μM |
| Description | Species |
|---|---|
| activated TAK1 mediates p38 MAPK activation | |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | |
| Activation of the AP-1 family of transcription factors | |
| ADP signalling through P2Y purinoceptor 1 | |
| c-src mediated regulation of Cx43 function and closure of gap junctions | |
| CD28 co-stimulation | |
| CD28 dependent PI3K/Akt signaling | |
| CD28 dependent Vav1 pathway | |
| CDO in myogenesis | |
| Circadian Clock | |
| Constitutive PI3K/AKT Signaling in Cancer | |
| CTLA4 inhibitory signaling | |
| DAP12 signaling | |
| DCC mediated attractive signaling | |
| Downstream signal transduction | |
| Downstream TCR signaling | |
| DSCAM interactions | |
| EPH-ephrin mediated repulsion of cells | |
| EPH-Ephrin signaling | |
| EPHA-mediated growth cone collapse | |
| EPHB-mediated forward signaling | |
| Ephrin signaling | |
| ERK/MAPK targets | |
| GAB1 signalosome | |
| Generation of second messenger molecules | |
| GP1b-IX-V activation signalling | |
| GPVI-mediated activation cascade | |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | |
| Integrin alphaIIb beta3 signaling | |
| Integrin cell surface interactions | |
| Interleukin-1 signaling | |
| Interleukin-2 signaling | |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human | |
| KSRP destabilizes mRNA | |
| Loss of Nlp from mitotic centrosomes | |
| Loss of proteins required for interphase microtubule organization from the ce | |
| NCAM signaling for neurite out-growth | |
| Nef and signal transduction | |
| Nef Mediated CD4 Down-regulation | |
| Netrin mediated repulsion signals | |
| Neurophilin interactions with VEGF and VEGFR | |
| NOD1/2 Signaling Pathway | |
| Oxidative Stress Induced Senescence | |
| p130Cas linkage to MAPK signaling for integrins | |
| p38MAPK events | |
| p75NTR recruits signalling complexes | |
| PD-1 signaling | |
| PECAM1 interactions | |
| Phosphorylation of CD3 and TCR zeta chains | |
| PIP3 activates AKT signaling | |
| Platelet sensitization by LDL | |
| Recruitment of mitotic centrosome proteins and complexes | |
| Regulation of KIT signaling | |
| Regulation of PLK1 Activity at G2/M Transition | |
| Signal regulatory protein (SIRP) family interactions | |
| Signaling by EGFR | |
| Signaling by ERBB2 | |
| Signaling by SCF-KIT | |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |
| Thrombin signalling through proteinase activated receptors (PARs) | |
| Tie2 Signaling | |
| Translocation of ZAP-70 to Immunological synapse | |
| VEGF binds to VEGFR leading to receptor dimerization | |
| VEGFA-VEGFR2 Pathway | |
| VEGFR2 mediated cell proliferation |
No pre-computed analogs available. Try a structural similarity search.